Sangamo BioSciences Announces Presentation Of Clinical Data From Alzheimer’s Disease Program
Data Demonstrate Long-Term Expression of Functional Nerve Growth Factor in the Brain and Stabilization of Brain Cell Metabolic Activity RICHMOND, Calif., Nov. 15, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today the presentation of positive data from the Phase 1 clinical trial of CERE-110 (AAV-NGF), a gene therapy approach designed to deliver nerve growth factor (NGF) for […]